Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Pulmonary embolism, Wheezing
Clinical narrative: he still wheezes a lot; was coming home with his shortness of breath; caller was told his lungs were full of blood clots; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (was coming home with his shortness of breath), PULMONARY EMBOLISM (caller was told his lungs were full of blood clots) and WHEEZING (he still wheezes a lot) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031660A and 024M20A) for COVID-19 vaccination.     No medical history was reported.  The patient's past medical history included Bypass surgery (triple (6 years ago)) in 2016.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced DYSPNOEA (was coming home with his shortness of breath) (seriousness criterion hospitalization) and PULMONARY EMBOLISM (caller was told his lungs were full of blood clots) (seriousness criteria hospitalization and medically significant). On an unknown date, the patient experienced WHEEZING (he still wheezes a lot) (seriousness criterion hospitalization). The patient was hospitalized for 4 days due to DYSPNOEA, PULMONARY EMBOLISM and WHEEZING. The patient was treated with ALBUTEROL SULFATE for Wheeze, at an unspecified dose and frequency and APIXABAN (ELIQUIS) ongoing since an unknown date for Clot blood, at an unspecified dose and frequency. At the time of the report, DYSPNOEA (was coming home with his shortness of breath) and WHEEZING (he still wheezes a lot) had not resolved and PULMONARY EMBOLISM (caller was told his lungs were full of blood clots) outcome was unknown.            There was no concomitant list.  Caller states in March, he walks a lot, was coming home with his shortness of breath and he could not understand it, he walked in and was kind of hanging in the walls, with shortness of breath. His wife took him to the Emergency room, and then they admitted him. He landed up in the hospital with his lungs full of blood clots, was in the hospital treated for 4 days with blood clots. Then he was released, and put him on blood thinner. In the hospital they did more testing and after 4 days they said caller was good to go, but caller states it has been 6 or 7 months and he still wheezes a lot, his family doctor got him an inhaler. Caller is still taking Eliquis, his heart doctor told him that they want to keep him on Eliquis because of the blood clots, caller states his arms get all boosted up with that, it happens when he bumps himself, stated that Eliquis does that.  Company Comment This case concerns a 78-year-old male patient with medical history of triple bypass, who experienced the serious unexpected event of special interest pulmonary embolism, serious unexpected events of dyspnoea, wheezing. The events pulmonary embolism and dyspnoea occurred on an unknown date on the next month after the second dose of Spikevax. Wheezing occurred on an unknown date after the second dose of Spikevax. The rechallenge was assessed as not applicable as the AEs occurred after the second dose. The medical history of triple bypass remains a confounder. The benefit-risk relationship of Spikevax is not affected by this report.; Sender's Comments: This case concerns a 78-year-old male patient with medical history of triple bypass, who experienced the serious unexpected event of special interest pulmonary embolism, serious unexpected events of dyspnoea, wheezing. The events pulmonary embolism and dyspnoea occurred on an unknown date on the next month after the second dose of Spikevax. Wheezing occurred on an unknown date after the second dose of Spikevax. The rechallenge was assessed as not applicable as the AEs occurred after the second dose. The medical history of triple bypass remains a confounder. The benefit-risk relationship of Spikevax is not affected by this report.